SG Americas Securities LLC decreased its position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 98.6% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 1,538 shares of the biopharmaceutical company’s stock after selling 105,643 shares during the period. SG Americas Securities LLC’s holdings in Alnylam Pharmaceuticals were worth $181,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in ALNY. Schwab Charles Investment Management Inc. raised its position in shares of Alnylam Pharmaceuticals by 33.4% during the second quarter. Schwab Charles Investment Management Inc. now owns 243,415 shares of the biopharmaceutical company’s stock valued at $19,415,000 after buying an additional 60,906 shares during the last quarter. State of Wisconsin Investment Board raised its position in shares of Alnylam Pharmaceuticals by 0.7% during the second quarter. State of Wisconsin Investment Board now owns 15,012 shares of the biopharmaceutical company’s stock valued at $1,197,000 after buying an additional 100 shares during the last quarter. Bank of New York Mellon Corp raised its position in shares of Alnylam Pharmaceuticals by 9.2% during the second quarter. Bank of New York Mellon Corp now owns 333,942 shares of the biopharmaceutical company’s stock valued at $26,634,000 after buying an additional 28,260 shares during the last quarter. Legal & General Group Plc grew its holdings in shares of Alnylam Pharmaceuticals by 12.7% in the second quarter. Legal & General Group Plc now owns 27,883 shares of the biopharmaceutical company’s stock valued at $2,224,000 after purchasing an additional 3,144 shares in the last quarter. Finally, State Board of Administration of Florida Retirement System grew its holdings in shares of Alnylam Pharmaceuticals by 2.1% in the second quarter. State Board of Administration of Florida Retirement System now owns 108,708 shares of the biopharmaceutical company’s stock valued at $8,671,000 after purchasing an additional 2,200 shares in the last quarter. Institutional investors own 88.39% of the company’s stock.

A number of research analysts recently weighed in on the stock. Needham & Company LLC raised their target price on shares of Alnylam Pharmaceuticals from $85.00 to $125.00 and gave the company a “buy” rating in a report on Wednesday, September 20th. Chardan Capital reissued a “buy” rating and issued a $124.00 target price on shares of Alnylam Pharmaceuticals in a report on Monday, September 25th. Piper Jaffray Companies reissued an “overweight” rating and issued a $116.00 target price (up from $110.00) on shares of Alnylam Pharmaceuticals in a report on Wednesday, September 20th. Sanford C. Bernstein reissued a “buy” rating and issued a $135.00 target price (up from $94.00) on shares of Alnylam Pharmaceuticals in a report on Thursday, September 21st. Finally, Cowen reissued an “outperform” rating and issued a $151.00 target price (up from $117.00) on shares of Alnylam Pharmaceuticals in a report on Friday, November 3rd. Three analysts have rated the stock with a sell rating, seven have issued a hold rating, fifteen have issued a buy rating and one has given a strong buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus price target of $121.85.

In other news, EVP Akshay Vaishnaw sold 33,666 shares of the business’s stock in a transaction on Monday, October 30th. The shares were sold at an average price of $121.46, for a total transaction of $4,089,072.36. Following the completion of the sale, the executive vice president now directly owns 45,201 shares of the company’s stock, valued at $5,490,113.46. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP Laurie Keating sold 30,000 shares of the business’s stock in a transaction on Friday, December 1st. The shares were sold at an average price of $135.89, for a total transaction of $4,076,700.00. Following the sale, the senior vice president now directly owns 41,500 shares of the company’s stock, valued at $5,639,435. The disclosure for this sale can be found here. Insiders have sold 322,646 shares of company stock valued at $41,185,315 over the last ninety days. 4.30% of the stock is owned by insiders.

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) opened at $123.96 on Monday. The company has a debt-to-equity ratio of 0.14, a quick ratio of 9.83 and a current ratio of 9.83. The company has a market cap of $12,300.00, a price-to-earnings ratio of -23.61 and a beta of 2.97. Alnylam Pharmaceuticals, Inc. has a one year low of $35.98 and a one year high of $147.63.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its quarterly earnings data on Tuesday, November 7th. The biopharmaceutical company reported ($1.34) EPS for the quarter, missing the consensus estimate of ($1.23) by ($0.11). The firm had revenue of $17.10 million for the quarter, compared to analysts’ expectations of $28.15 million. Alnylam Pharmaceuticals had a negative return on equity of 46.94% and a negative net margin of 664.70%. The firm’s quarterly revenue was up 24.8% compared to the same quarter last year. During the same period in the previous year, the firm earned ($1.21) earnings per share. equities analysts anticipate that Alnylam Pharmaceuticals, Inc. will post -5.21 EPS for the current fiscal year.

ILLEGAL ACTIVITY WARNING: This piece was originally published by TheOlympiaReport and is the property of of TheOlympiaReport. If you are viewing this piece on another publication, it was illegally copied and republished in violation of international copyright law. The legal version of this piece can be viewed at https://theolympiareport.com/2017/12/25/alnylam-pharmaceuticals-inc-alny-holdings-reduced-by-sg-americas-securities-llc.html.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs (siRNAs).

Want to see what other hedge funds are holding ALNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY).

Institutional Ownership by Quarter for Alnylam Pharmaceuticals (NASDAQ:ALNY)

Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.